 Home > Medical News > Latest Medical News > Two injections of Shutaishen have been accepted for new drug clinical trials

Two injections of Shutaishen have been accepted for new drug clinical trials

 Last Update: 2021-08-12
 Source: Internet
 Author: User

Tags

ketorolac injection

copaxone injection

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 21, Shutaishen announced that BDB-001 injection (ANCA-related vasculitis indication) was accepted for clinical trials of new drugs; STSA-1002 injection was accepted for clinical trials of new drugs by the US FDA

BDB-001 Injection This application is a new indication and is intended to be used for the treatment of anti-neutrophil cytoplasmic antibody-related vasculitis

STSA-1002 injection is a recombinant anti-human C5a IgG1 fully human monoclonal antibody targeting C5a.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.